Title Molecular and functional characterisation of a novel intragenic 12q24.21 deletion resulting in MED13L haploinsufficiency syndrome /
Authors Siavrienė, Evelina ; Petraitytė, Gunda ; Mikštienė, Violeta ; Maldžienė, Živilė ; Sasnauskienė, Aušra ; Žitkutė, Vilmantė ; Ambrozaitytė, Laima ; Rančelis, Tautvydas ; Utkus, Algirdas ; Kučinskas, Vaidutis ; Preikšaitienė, Eglė
DOI 10.3390/medicina59071225
Full Text Download
Is Part of Medicina.. Basel : MDPI. 2023, vol. 59, iss. 7, art. no. 1225, p. [1-14].. ISSN 1010-660X. eISSN 1648-9144
Keywords [eng] MED13L haploinsufficiency syndrome ; intellectual disability ; congenital anomalies ; molecular and functional analysis ; CRISPR-Cas9
Abstract [eng] Background and Objectives: Heterozygous pathogenic variants in the MED13L gene cause impaired intellectual development and distinctive facial features with or without cardiac defects (MIM #616789). This complex neurodevelopmental disorder is characterised by various phenotypic features, including plagiocephaly, strabismus, clubfoot, poor speech, and developmental delay. The aim of this study was to evaluate the clinical significance and consequences of a novel heterozygous intragenic MED13L deletion in a proband with clinical features of a MED13L-related disorder through extensive clinical, molecular, and functional characterisation. Materials and Methods: Combined comparative genomic hybridisation and single-nucleotide polymorphism array (SNP-CGH) was used to identify the changes in the proband’s gDNA sequence (DECIPHER #430183). Intragenic MED13L deletion was specified via quantitative polymerase chain reaction (qPCR) and Sanger sequencing of the proband’s cDNA sample. Western blot and bioinformatics analyses were used to investigate the consequences of this copy number variant (CNV) at the protein level. CRISPR-Cas9 technology was used for a MED13L-gene-silencing experiment in a culture of the control individual’s skin fibroblasts. After the MED13L-gene-editing experiment, subsequent functional fibroblast culture analyses were performed. Results: The analysis of the proband’s cDNA sample allowed for specifying the regions of the breakpoints and identifying the heterozygous deletion that spanned exons 3 to 10 of MED13L, which has not been reported previously. In silico, the deletion was predicted to result in a truncated protein NP_056150.1:p.(Val104Glyfs*5), partly altering the Med13_N domain and losing the MedPIWI and Med13_C domains. After MED13L gene editing was performed, reduced cell viability; an accelerated aging process; and inhibition of the RB1, E2F1, and CCNC gene expression were found to exist. Conclusions: Based on these findings, heterozygous intragenic 12q24.21 deletion in the affected individual resulted in MED13L haploinsufficiency due to the premature termination of protein translation, therefore leading to MED13L haploinsufficiency syndrome.
Published Basel : MDPI
Type Journal article
Language English
Publication date 2023
CC license CC license description